Experimental virus therapy for advanced cancers tested in early trial

NCT ID NCT05839600

First seen May 26, 2026 · Last updated Jun 17, 2026 · Updated 8 times

Summary

This early-phase study tested a new medicine called BI 1821736 in 10 adults with advanced solid tumors that had not responded to other treatments. BI 1821736 is a special virus designed to kill cancer cells and help the immune system fight cancer. Participants received the drug by infusion every 3 weeks for up to 3 months, and doctors monitored safety and tumor response. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Quiron. I.C.U.

    Barcelona, 08023, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Instituto Valenciano de Oncología

    Valencia, 46009, Spain

  • Karolinska Universitetssjukhuset Stockholm

    Stockholm, 17177, Sweden

  • NEXT Oncology-San Antonio-65273

    San Antonio, Texas, 78229, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Yale Cancer Center

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.